From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study
Strategy
Cost
Δ Cost
QALY
Δ QALY
ICER
Standard Care
33371.7
0.7677
Dexamethasone
33555.6
183.9
0.8028
0.0352
5229.1
Remedesivir
32388.4
-983.3
0.7736
0.0059
Dominant
Rem + Dex
32572.2
-799.4
0.8087
0.0411